

## Disclosures

### Personal Commercial (16)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbvie	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
CinRx	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Corviamedical	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
duke clinical reseach institute	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Gilead	Other	Significant ( $\geq$ \$5,000)	<i>General Cardiology</i>
GlaxoSmithKline	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant ( $\geq$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
National Institutes of Health	Research/Research Grants	Significant ( $\geq$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Novartis	Research/Research Grants	Significant ( $\geq$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Relypsa	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
S. Luke's Medical Cdenter	Consultant Fees/Honoraria	Modest ( $<$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
St. Luke's Medical Center	Research/Research Grants	Significant ( $\geq$ \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
wake forest school of medicine	Salary	Significant ( $\geq$ \$5,000)	<i>General Cardiology</i>

### Personal Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Principal Investigator, Co-Investigator, and DSMB member for NIH funded studies <i>† Federal Government</i>	Other	Significant ( $\geq$ \$5,000)	<i>Heart Failure and Cardiomyopathies Other</i>

### Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

# Agreement

---

Certified Education Attestation | Signed on 11/16/2018

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/16/2018

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

Embargo | Signed on 11/16/2018

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

On-Going Obligation Agreement | Signed on 11/16/2018

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.